rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
Language Development Deficits and Early Interactive Music Intervention
Status: Not yet recruiting

Investigators compare effects of 6-month music versus circus group interventions on language development in infants and toddlers with or without familial risk for dyslexia (anticipated total N=200). Effects of intervention timing, dyslexia risk and genetics, and social-emotional factors on the intervention outcomes are investigated.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  8-12 months old at start of intervention (recruited between 0-11 months) Born healthy and at term (gestational age at least 37 weeks and birth weight at least 2500 g) Normal hearing at birth (evoked oto-acoustic emissions conducted to newborns routinely at the hospital) At least one caregiver living with the child is native speaker of Finnish and speaks Finnish to the child Risk group: At least one biological parent has developmental dyslexia according to a recent (<5 years) diagnostic statement by a health care professional or according to a dyslexia test at study enrollment; symptoms have started in childhood  Exclusion Criteria:  Medication affecting the central nervous system Sensory deficits Serious health conditions No-risk group: Suspected dyslexia or developmental language disorder due to symptoms that have started in childhood in either of the biological parents; diagnosis of a developmental or language disorder (incl. dyslexia, developmental language disorder, attention-deficit/hyperactivity disorder ADHD, attention-deficit disorder ADD) or neurological disorder in either of the biological parents Risk group: Diagnosis of ADHD, ADD, or other not-language-related developmental disorder in either of the biological parents; in the dyslexic parent, brain trauma in childhood that may indicate a non-heritable cause for the reading deficit or individualized school curriculum that may indicate broader developmental deficits. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 8 Months - MaximumAge: 12 Months - StdAgeList: Child
OncoSweep Cancer Spotlight and Spectrum Product Line
Status: Recruiting

CONQUER cancer study: To collect blood samples from cancer and non-cancer participants for development and validation of the 'OncoSweep Cancer Spotlight and Spectrum Product Line'

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Inclusion  Individual who is not mentally impaired, capable to read, understand, and is willing to provide signed and dated informed consent form. Individual is aged 18 years old or above.  Individual who is willing to provide information on the given questionnaire. Test group: Individual was diagnosed with pulmonary nodules or masses by low-dose CT (LDCT)/ CT, and evaluated by the physician needed to conduct a biopsy or/ and surgery has been arranged.  Control group: Individual is willing to undergo LDCT or CT scan with 3-5 mm spatial z-axis resolution, pulmonary function examination, X-ray, laboratory blood test, and blood drawing.  Control group: Individual has no abnormal finding from LDCT or CT scan with 3-5 mm spatial z-axis resolution and pulmonary function examination(FEV1/FVC Ratio≧70%). Individual did not donate blood or receive blood transfusion within two months before joining the study.  Exclusion Criteria:  Exclusion  Individual who is not suitable for participating as per Investigator's judgement. Individual who has undergone gene therapy or related product within one year prior to enrolling in this study. Individual who is attending another clinical study at the time of enrollment. Individual who is known to be pregnant. Individual who has received a vaccine within two weeks. Individual who has a history of any cancer occurrences other than lung cancer. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: This is a two-arm, open-label, non-randomized controlled pilot study intended to screen adults of 18 years or older, who are treatment-naïve for cancers, or who have pulmonary nodules or masses detected by LDCT or standard CT scan, utilizing OncoSweep Lung Spotlight with venous blood sample collected in the healthcare facility where the study is being conducted. - SamplingMethod: Non-Probability Sample
Strip Graft w/ Xenogeneic Matrix vs Free Gingival Graft for the Augmentation of Peri-implant Keratinized Mucosa
Status: Recruiting

The primary objective of this study is to compare changes in peri-implant keratinized mucosa (PIKM) following the application of apically repositioned flap (ARF) using a combination of a Strip graft and a Xenogeneic matrix, or with a free gingival graft (FGG), in implants in the second stage with <2 mm of PIKM.

Additionally, as a secondary objective, the investigators compare postoperative blood supply in both recipient and donor sites based on the type of graft obtained. Meanwhile, the investigators evaluate differences between the two groups concerning microcirculation values (perfusion units, PU), soft tissue thickness (STT), volume change, vestibular depth, as well as clinical, aesthetic, and patient-reported outcome measures (PROMS).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients older than 18 years Short-span dental implants in the mandible at second stage with inadequate PIKM (<2 mm) with at least one adjacent tooth mesially Periodontally healthy patients with a pristine or reduced periodontium Plaque index (FMPS) less than 20%.  Exclusion Criteria:  Compromised general health status that contraindicates study procedures (≥ASA III); Drug or alcohol abuse; Smoking of > 10 cigarettes per day; Chronic use of corticosteroids, NSAIDs or immunomodulators (any type or dose); Pregnant or lactating women; History of previous mucogingival surgeries in the area of interest - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - MaximumAge: 80 Years - StdAgeList: Adult, Older Adult
Association Between Lifetime Physical Activity and Exercise and the Development of Wild-type Transthyretin Amyloid Cardiomyopathy
Status: Recruiting

The aim of this study is to investigate the association between increased lifetime physical activity and the development of wild-type transthyretin amyloid cardiomyopathy.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Confirmed diagnosis of wtATTR-CM including sequencing of the TTR gene; or HFpEF; or HFrEF; or healthy proband without a diagnosis of heart failure Initial diagnosis of respective cardiac disease (wtATTR-CM, HFpEF, HFrEF) after the 6th decade of life; or no cardiac disease (healthy control) Willingness and ability to provide signed informed consent form (ICF) Age > 60 years  Exclusion Criteria:  History of severe chronic illness limiting the ability to perform physical activity during the 3rd to 6th decade A diagnosis of dementia or cognitive impairment Any other reason resulting in the inability to perform the questionnaire and/or interview - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 60 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Number of participants: 252 The study population will comprise four subgroups (n=63 in each group)  cardiac wild type transthyretin amyloidosis (wtATTR-CM); heart failure with preserved ejection fraction (HFpEF); heart failure with reduced ejection fraction (HFrEF; ischemic or inflammatory origin); healthy controls - SamplingMethod: Non-Probability Sample
Low Dose Aspirin for Prevention of Early Pregnancy Loss
Status: Recruiting

Preeclampsia is a pregnancy-specific, multisystem disorder affecting 3% to 8% of pregnancies and remains a significant cause of maternal and neonatal morbidity and mortality worldwide.

The World Health Organization estimates that approximately 76,000 maternal deaths annually are attributed to preeclampsia, accounting for 16% of global maternal mortality, with the majority occurring in low- and middle-income countries

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Singleton pregnancy Before 8 weeks gestation Women at high risk of preeclampsia according to Royal College of Obstetricians and Gynecologists (RCOG) (Robson et al., 2013): Maternal age ≥ 35 years. Nulliparity. BMI ≥ 30 kg/m2. Smoking of r ≥ 10 cigarettes per day. Previous history of small for gestational age (SGA) baby. Previous history of stillbirth. Pregnancy interval < 6 months or ≥ 60months. Chronic hypertension. Diabetes with vascular disease. Willingness to participate in the study and provide informed written consent.  Exclusion Criteria:  Known allergy or hypersensitivity to aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) Use of any anticoagulant medication (e.g., heparin, warfarin, clopidogrel) Use of low-dose aspirin for any indication prior to the current pregnancy Chronic use of NSAIDs or corticosteroids History of bleeding disorder or active bleeding Any medical condition that may contraindicate the use of low-dose aspirin (e.g., peptic ulcer disease, asthma, liver, or kidney disease) Multiple gestation Inability to provide informed consent or comply with the study requirements. - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - MaximumAge: 40 Years - StdAgeList: Adult
Active Surveillance for Low-risk Papillary Thyroid Carcinoma
Status: Not yet recruiting

This study is an observational cohort study targeting patients with low-risk Papillary thyroid cancer who opted for active surveillance or immediate surgery based on a sufficient understanding of the treatment options. The primary objective of the study is to evaluate progression free survival of the patients with low-risk Papillary thyroid cancer who choose active surveillance, in other words, to observe the natural course of low-risk Papillary thyroid cancer.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  subjects over 18 years old with a thyroid nodule of ≤ 1.5 cm in maximum diameter and a Bethesda category V or VI diagnosis on cytopathology subjects without high-risk features, including lymph node (LN) metastasis, distant metastasis, signs or symptoms of invasion to the recurrent laryngeal nerve or trachea, Poorly differentiated cancer or variant with a poor prognosis, such as the tall cell, diffuse sclerosing, columnar cell, or solid variants.  Exclusion Criteria:  subjects who are unable or unwilling to attend regular follow-ups.. subjects with a diagnosis of benign, atypia of undetermined significance, suspicious for follicular neoplasm, or follicular neoplasm (Bethesda category II, III, or IV) based on Fine needle aspiration or, or benign, indeterminate by core needle biopsy. - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Subjects aged older than 18 years with the tumor size of ≤ 1.5 cm papillary thyroid carcinoma, who meet the inclusion criteria from Seoul National University Hospital, National Cancer Center, Seoul National University Bundang Hospital, and SMG-SNU Boramae Medical Center. - SamplingMethod: Probability Sample
Population Pharmacokinetic Model of Amikacin and Vancomycin in Critically Ill Patients
Status: Recruiting

The object of the scientific research is the characterization of the pharmacokinetic profile and the investigation of factors of pharmacokinetic variability of amikacin and vacnomycin in critically ill patients with a diagnosis of sepsis-like condition (SIRS), hospital-acquired sepsis and/or septic shock and who are on extracorporeal therapy with Cytosorb® and Oxiris® adsorbents.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  diagnosis of SIRS, sepsis and/or septic shock, older than 18 years, who are being treated with amikacin and/or vancomycin, length of use of adsorbent at least 12 hours.  Exclusion Criteria:  contraindication for hemodiafiltration with adsorbents, patients under the age of 18, terminal cancer patients. - HealthyVolunteers: No - Gender: All - StdAgeList: Child, Adult, Older Adult - StudyPopulation: Adult critically ill patients with a diagnosis of SIRS, sepsis and/or septic shock who are hospitalized in the Department of Medical Intensive Care Medicine - SamplingMethod: Non-Probability Sample
Preoperative Nutritional Status Associated With Delayed Discharge in Elderly Patients Undergoing Gastrectomy
Status: Not yet recruiting

Gastric cancer (GC) remains the 5th most common cancer worldwide and had the second- highest mortality rate in China. The population of elder patients with GC has been increasing because of the high prevalence of H. pylori infection and increasing life expectancy. Elderly GC patients face several challenges during treatment, such as comorbidities, organ dysfunction, immunosuppression, and delayed recovery. Advanced age is associated with a higher rate of postoperative complications shortly after surgical treatment, and lower 5-year overall survival as long-term outcome.

In China, the prevalence of malnutrition in hospitalized patients is around 12.6% to 46.19%. Malnutrition is one of the great risk factors of adverse clinical outcomes in elderly patients with GC. The nutritional status at the time of diagnosis was independently associated with postoperative complications, overall survival, and disease-free survival. The condition can be caused by mechanical obstruction of the digestive tract or anorexia-cachexia syndrome, leading to insufficient protein or energy intake and absorption disorder. Nutrition screening, assessment, and intervention are important steps in nutritional management.

Previous studies mostly focused on hospitalized internal medical patients. Only a few studies focused on surgical patients regardless of age. Therefore, in this retrospective study, we are going to investigate the nutritional status and perioperative nutritional support of geriatric surgical patients with GC, and provide a basis for implementing an effective nutritional intervention.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients aged 60-90 years old; Patients with gastric cancer; Patients who underwent radical gastrectomy. -  Exclusion Criteria:  Patients with other malignancies; Patients with previous gastrointestinal surgery or emergency surgery; Patients with incomplete medical record.  - - HealthyVolunteers: No - Gender: All - MinimumAge: 60 Years - MaximumAge: 90 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Patients aged 60-90 years old with gastric cancer who underwent radical gastrectomy were retrospectively analyzed from the prospectively collected database of Zhongshan Hospital of Fudan University between March 2024 and December 2024. - SamplingMethod: Probability Sample
The Effect of Using a Kaleidoscope on Fear and Pain in Children
Status: Recruiting

The research was conducted in randomized controlled experimental type between May 2022 and December2023. The universe of the research consisted of children and their parents who were diagnosed with a fracture, applied to the Orthopedic outpatient clinic and Emergency department of the Erzurum Ataturk University Health Research and Application Center and referred to the Orthopedic clinic, and decided to undergo a cast procedure for treatment. The sample of the research consisted of a total of 70 children and their parents, including 35 control groups and 35 kaleidoscope groups, who met the research criteria from this universe. The children in the kaleidoscope group were shown the kaleidoscope. No intervention other than routine application was applied to the control group. "Introductory Information Form", "Wong-Baker Facial Expressions Rating Scale and Child Fear Scale were used in the collection of data.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Being a child in the 6-12 age group, The child's willingness to participate in the study, The parent's volunteering to participate in the study, Absence of intellectual disability of the child and parent, The child and the parent speak Turkish and are open to communication.  Exclusion Criteria:  The child has a chronic disease that can cause pain, The child has used analgesics within 24 hours before admission to the hospital, The child has visual impairment. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 6 Years - MaximumAge: 12 Years - StdAgeList: Child
Telerehabilitation-Based Early Upper Extremity Training in Stroke Patients
Status: Recruiting

Telerehabilitation method, which is an alternative to face-to-face rehabilitation practices for stroke patients who need intensive, regular and long-term rehabilitation in the early period, has been popularly used in recent years. Telerehabilitation is a practice in which the patient participates in the treatment via digital media without the need for the patient to come to the clinic.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Between the ages of 30-65, with a history of stroke within the last month, Mini Mental Score ≥ 24, 1-10 after discharge. on the day, patients who can sit for at least 30 seconds, exhibit a hemiparetic condition, and are clinically stable  Exclusion Criteria:  Flaccid hemiplegia detected by anamnesis and physical examination, Has spasticity in the upper extremity with a severity greater than 1+ according to the Modified Ashworth Scale, patients with severe dementia and dysfunction of the upper extremity joints due to a previous musculoskeletal disease - HealthyVolunteers: No - Gender: All - MinimumAge: 30 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder
Status: Not yet recruiting

To learn about the safety and effects of low-dose sirolimus in participants with RUNX1-FPD.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Participants has provided signed, informed consent before initiation of any study specific procedures Aged ≥18 years at the time of signing the informed consent Confirmed P/LP germline RUNX1 variant per ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) RUNX1-specific variant curation rules80 Participants must be willing to provide bone marrow sample at time of screening and at the end of treatment with sirolimus Platelet count of ≥50,000/µL Adequate renal function: estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation, >30 mL/min/1.73m2 Adequate hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3 × upper limit of normal (ULN) and total bilirubin <1.5 × ULN Adequate cardiac function: left ventricular ejection fraction >50%  Exclusion Criteria:  Known allergy to sirolimus History of lymphoma or other hematologic malignancies Uncontrolled bleeding Any prior diagnosis of myelodysplastic syndrome or other hematologic malignancy using International Working Group criteria Prior treatment with sirolimus or a rapalog, mTOR inhibitor, or B-cell-depleting therapy within 28 days before study day 1 Treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4; eg, ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, and clarithromycin), strong inducers of CYP3A4 (eg, rifampin and rifabutin), other drugs that could increase sirolimus blood concentrations (eg, bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors [eg, ritonavir, indinavir, boceprevir, and telaprevir], metoclopramide, nicardipine, troleandomycin, and verapamil), other drugs that could decrease sirolimus blood concentrations (eg, carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort [Hypericum perforatum]), or drugs with blood concentrations that could increase (eg, verapamil) within 7 days before study day 1 Use of cannabidiol, which can increase blood levels of sirolimus, within 7 days before study day 1 Myocardial infarction within 6 months before study day 1, congestive heart failure (New York Heart Association > class II) Total cholesterol >300 mg/dL or triglyceride >400 mg/dL Arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months before study day 1 Infection requiring intravenous anti-infective treatment within 1 week of study day 1 Live vaccines (eg, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid) within 28 days before study day 1 Known diagnosis of chronic viral infection (eg, hepatitis B or C or HIV, and Epstein-Barr) or tuberculosis Women who are pregnant, may become pregnant, or who are breastfeeding - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
A Study of Sex Differences in Neurocirculatory Control
Status: Not yet recruiting

The purpose of this study is to investigate potential sex differences in neurocirculatory control of blood pressure in patients with untreated obstructive sleep apnea (OSA).

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  20-70 years of age  Exclusion Criteria:  Coronary artery disease Heart failure Pregnancy COPD Diabetes CKD Sleep disorders other than OSA Shift workers Individuals who typically go to sleep after midnight Individuals who traveled across ≥2 time zones within one week of study visits BMI ≥40.0kg/m2 Use of nicotine-containing products within the two years preceding study visits Use of allopurinol, proton pump inhibitors, or other medications/supplements which interfere with outcome measures - Gender: All - MinimumAge: 20 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Subjects with or without untreated obstructive sleep apnea will be recruited from Mayo Clinic in Rochester, MN. - SamplingMethod: Non-Probability Sample
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects With Discoid Lupus Erythematosus
Status: Not yet recruiting

This study is a single-blind, intraindividual study to evaluate the efficacy of ruxolitinib 1.5 % cream in adult subjects with discoid lupus erythematosus.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male or female subject 18 years of age or older at the time of consent. Confirmed DLE diagnosis. Subject has moderate to severe DLE, as defined by an overall CLA IGA score of 3 (moderate) or 4 (severe) at screening and Day 1. Female subject of childbearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test at Day 1. Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study-related procedures. Subjects must be willing to comply with all study procedures and must be available for the duration of the study.  Exclusion Criteria:  Female subject who is breastfeeding, pregnant, or who is planning to become pregnant during the study. Subject has a history of skin disease or presence of skin condition that would interfere with the study assessments. Subject has unstable or fluctuating use of nicotine-containing products within 4 weeks prior to screening. Subject is known to have immune deficiency or is immunocompromised. Subject is ≥ 50 years old AND has a history of heart attack, other clinically significant heart problems, stroke, or blood clots. Subject is known to have hepatitis B or hepatitis C viral infection. Subject has used any topical medicated treatment that could affect DLE within 2 weeks prior to Day 1, including, but not limited to, topical corticosteroids, retinoids, calcineurin inhibitors, antimicrobials, and medical devices. Subject has received any marketed or investigational biological agent within 12 weeks or 5 half lives (whichever is longer) prior to Day 1, including but not limited to ustekinumab and rituximab. Subject is currently receiving a nonbiological investigational product or device or has received one within 4 weeks prior to Day 1. Subject has a known or suspected allergy to ruxolitinib. Subject has used ruxolitinib cream (OpzeluraTM). Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult